While we wait for a vaccine against SARS-CoV-2, why not think about available drugs?

Abstract: At the time of reception of this article (April 2, 2020), efforts to develop a specific vaccine against SARS-Cov-2, the causative agent of the coronavirus disease 2019 (COVID-19), had just begun trial phase 1, but full validation of this and other current developments is likely to take...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Barrantes, Francisco José
Formato: Artículo
Lenguaje:Inglés
Publicado: Frontiers Media 2022
Materias:
COVID-19
VACUNACION
PROFILAXIS
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/14224
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139-123456789-14224
record_format dspace
spelling I33-R139-123456789-142242023-11-22T22:13:26Z While we wait for a vaccine against SARS-CoV-2, why not think about available drugs? Barrantes, Francisco José COVID-19 VACUNACION PROFILAXIS Abstract: At the time of reception of this article (April 2, 2020), efforts to develop a specific vaccine against SARS-Cov-2, the causative agent of the coronavirus disease 2019 (COVID-19), had just begun trial phase 1, but full validation of this and other current developments is likely to take many more months to reach completion. The ongoing pandemic constitutes a major health burden of world proportions that is also having a devastating impact on whole economies worldwide, the knock-on effects of which could be catastrophic especially in poorer countries. Alternative measures to ameliorate the impact and hamper or minimally slow down disease progression are urgently called for. This review discusses past and currently evolving data on the etiological agent of the current pandemic, SARS-CoV-2, and its host cell receptors with a view to disclosing alternative drugs for palliative or therapeutic approaches. Firstly, SARS-CoV-2 exhibits marked tropism for cells that harbor the membrane-bound metalloprotease angiotensin-converting enzyme 2 (ACE2) at their plasmalemma, predominantly in cells lining the oral cavity, upper respiratory tract, and bronchoalveolar cells, making these epithelial mucosae the most likely viral receptor cell targets and entry routes. Secondly, the crystal structures of several coronavirus spike proteins in complex with their cell host target receptors, and of SARS-Cov-2 in complex with an inhibitor, are now available at atomic resolution through X-ray diffraction and cryo-electron microscopy studies. Thirdly, viral entry of other viruses has been successfully blocked by inhibiting viral endogenous proteases or clathrin/dynamin-dependent endocytosis, the same internalization pathway followed by ACE2 and some viruses. Fourthly, the target cell-surface receptor molecules and SARS-CoV-2 possess other putative sites for drugs potentially modulating receptor activity or virus processing. A multi-pronged pharmacological approach attacking more than one flank of the viral-receptor interactions is worth considering as a front-line strategy. 2022-06-22T12:26:13Z 2022-06-22T12:26:13Z 2020 Artículo Barrantes, F.J. While we wait for a vaccine against SARS-CoV-2, why not think about available drugs? [en línea]. Frontiers in Physiology. 2020, 11:820 doi:10.3389/fphys.2020.00820 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/14224 1664-042X https://repositorio.uca.edu.ar/handle/123456789/14224 10.3389/fphys.2020.00820 32719619 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Frontiers Media Frontiers in Physiology. 2020, 11:820
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic COVID-19
VACUNACION
PROFILAXIS
spellingShingle COVID-19
VACUNACION
PROFILAXIS
Barrantes, Francisco José
While we wait for a vaccine against SARS-CoV-2, why not think about available drugs?
topic_facet COVID-19
VACUNACION
PROFILAXIS
description Abstract: At the time of reception of this article (April 2, 2020), efforts to develop a specific vaccine against SARS-Cov-2, the causative agent of the coronavirus disease 2019 (COVID-19), had just begun trial phase 1, but full validation of this and other current developments is likely to take many more months to reach completion. The ongoing pandemic constitutes a major health burden of world proportions that is also having a devastating impact on whole economies worldwide, the knock-on effects of which could be catastrophic especially in poorer countries. Alternative measures to ameliorate the impact and hamper or minimally slow down disease progression are urgently called for. This review discusses past and currently evolving data on the etiological agent of the current pandemic, SARS-CoV-2, and its host cell receptors with a view to disclosing alternative drugs for palliative or therapeutic approaches. Firstly, SARS-CoV-2 exhibits marked tropism for cells that harbor the membrane-bound metalloprotease angiotensin-converting enzyme 2 (ACE2) at their plasmalemma, predominantly in cells lining the oral cavity, upper respiratory tract, and bronchoalveolar cells, making these epithelial mucosae the most likely viral receptor cell targets and entry routes. Secondly, the crystal structures of several coronavirus spike proteins in complex with their cell host target receptors, and of SARS-Cov-2 in complex with an inhibitor, are now available at atomic resolution through X-ray diffraction and cryo-electron microscopy studies. Thirdly, viral entry of other viruses has been successfully blocked by inhibiting viral endogenous proteases or clathrin/dynamin-dependent endocytosis, the same internalization pathway followed by ACE2 and some viruses. Fourthly, the target cell-surface receptor molecules and SARS-CoV-2 possess other putative sites for drugs potentially modulating receptor activity or virus processing. A multi-pronged pharmacological approach attacking more than one flank of the viral-receptor interactions is worth considering as a front-line strategy.
format Artículo
author Barrantes, Francisco José
author_facet Barrantes, Francisco José
author_sort Barrantes, Francisco José
title While we wait for a vaccine against SARS-CoV-2, why not think about available drugs?
title_short While we wait for a vaccine against SARS-CoV-2, why not think about available drugs?
title_full While we wait for a vaccine against SARS-CoV-2, why not think about available drugs?
title_fullStr While we wait for a vaccine against SARS-CoV-2, why not think about available drugs?
title_full_unstemmed While we wait for a vaccine against SARS-CoV-2, why not think about available drugs?
title_sort while we wait for a vaccine against sars-cov-2, why not think about available drugs?
publisher Frontiers Media
publishDate 2022
url https://repositorio.uca.edu.ar/handle/123456789/14224
work_keys_str_mv AT barrantesfranciscojose whilewewaitforavaccineagainstsarscov2whynotthinkaboutavailabledrugs
_version_ 1807949127816839168

Ejemplares similares